ARHGEF11

Across TCGA pan-cancer cohorts, ARHGEF11 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARHGEF11 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGEF11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where ARHGEF11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.341	1.000	.014	25	view →
PDAC	OS	Median	III,IV	0.915	0.592	.002	14	view →
LUAD	DFS	Quartile	II,III,IV	0.285	0.774	.007	9	view →
GBM	DFS	Tertile	All	0.905	0.685	.032	7	view →
UCEC	OS	Median	All	0.980	0.849	.008	2	view →
CCRCC	DFS	Tertile	All	0.887	0.635	.030	1	view →
LSCC	DFS	Tertile	All	0.986	0.865	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARHGEF11–HNSC (DFS)

Open the HNSC breakdown →